Statistics from Altmetric.com
Question Can oestrogen plus progestin prevent recurrent non-fatal myocardial infarction (MI) and coronary heart disease (CHD) mortality in postmenopausal women with established CHD?
Randomised, double blind, placebo controlled trial with mean follow up of 4.1 years (Heart and Estrogen/progestin Replacement Study [HERS]).
20 outpatient and community settings in the US.
2763 postmenopausal women between 44 and 79 years of age (mean age 67 y, 89% white) with established CHD who had not had a hysterectomy. Exclusion criteria were CHD event ≤6 months before study; sex hormone use ≤3 months before study; history of breast cancer, deep vein thrombosis, pulmonary embolism, hyperplasia, or endometrial cancer; abnormal mammogram or Papanicolaou test; increased serum triglyceride or serum aspartate aminotransferase concentrations; geographic inaccessibility; other fatal disease; congestive heart failure; alcoholism or drug abuse; uncontrolled hypertension or diabetes; participation in another study; <80% compliance with prestudy placebo; or intolerance to hormone therapy. Follow up was 100%. …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.